Category Archives: Global

Market Access in Ukraine

by Lana Sinichkina  and Leonid Cherniavskyi. On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy. In line with the signed AA, the government has adopted a detailed implementation plan, which endorses for preparation and approval by the […]
Also posted in Europe, Guest Blog, healthcare, Op-Ed, pricing, Regulatory | Tagged , , , | Leave a comment

US Company Awarded UK's First "Promising Innovative Medicine" Designation

By Leela Barham. The UK’s Medicines and Healthcare Regulatory Authority (MHRA) has awarded Northwest Biotherapeutics, Inc. (Bethesda, MD) the very first “Promising Innovative Medicine”, or PIM designation, for the company’s DCVax-L product.
Also posted in Europe, Guest Blog, Regulatory | Tagged , , , | Leave a comment

Europe and Canada Welcome Trade Agreement Text

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D) have welcome finalization of the text for the Comprehensive Economic and Trade Agreement (CETA). CETA represents the first free trade agreement between any G8 country. EFPIA and Rx&D believe it will, once in place, be beneficial to patients on both […]
Also posted in Europe, Strategy | Tagged , , | Leave a comment

Hemispherx’s Five Ebola Research Collaborations

Hemispherx Biopharma (Philadelphia, PA) has announced a  set of research collaborations designed to develop “therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation”.
Also posted in Biotech, healthcare, R&D | Tagged , , | Leave a comment

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Also posted in Europe, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta